Market Overview

Morgan Stanley Upgrades Gilead Sciences To Overweight, Shares Rise

Share:
Related GILD
Analysts On Gilead: We Think They're Mobilizing For A Deal
Gilead's Q1 Fails To Impress, But Strength Of Pipeline Not Reflected In Current Share Price
Woodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen Inc, Sells ... (GuruFocus)

Analysts at Morgan Stanley upgraded Gilead Sciences Inc. (NASDAQ: GILD) from undefined to Overweight.

Gilead Sciences shares have jumped 24.92% over the past 52 weeks, while the S&P 500 index has gained 13.45% in the same period.

Gilead Sciences' shares rose 1.92% to $95.59 in pre-market trading.

Latest Ratings for GILD

DateFirmActionFromTo
Mar 2017UBSDowngradesBuyNeutral
Feb 2017CitigroupDowngradesBuyNeutral
Nov 2016Stifel NicolausInitiates Coverage OnBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Morgan StanleyUpgrades Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!